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A B S T R A C T
Objectives: Appropriate clinical staging of malignant pleural mesothelioma (MPM) is critical for correct treat-
ment decisions. Newly revised TNM staging protocol has been released for MPM. We investigated baseline
computed tomography (CT) characteristics of MPM patients, the new staging system and a simple tumor size
(TS) assessment in terms of survival.
Materials and methods: As part of our study that included all MPM patients diagnosed in Finland 2000–2012, we
retrospectively reviewed 161 CT scans of MPM patients diagnosed between 2007 and 2012 in the Hospital
District of Helsinki and Uusimaa. TS was estimated by using the maximal tumor thickness and grading tumor
extension along the chest wall. Cox Regression models were used to identify relationships between survival,
clinicopathological factors and CT-findings.
Results: The median length of follow-up was 9.7 months and the median survival 9.1 months. The right sided
tumors tended to be more advanced at baseline and had worse prognosis in the univariate analyses. In the
multivariate survival model, TS, pleural effusion along with non-epithelioid histology were predictors of poor
survival. Tumor size correlated significantly with a sarcomatoid histopathological finding and several para-
meters linked to a more advanced TNM stage. Most patients were diagnosed with locally advanced stage, while
12 (7%) had no sign of the tumor in CT.
Conclusion: In this study, we demonstrate a novel approach for MPM tumor size evaluation that has a strong
relationship with mortality, sarcomatoid histology and TNM stage groups. TS could be used for prognostic
purposes and it may be a useful method for assessing therapy responses.
1. Introduction
Malignant pleural mesothelioma (MPM) is a rare cancer that arises
from the surface of pleural mesothelial cells [1]. The main etiological
factor is asbestos exposure with a latency period of 15 years or more
[2]. The prognosis of MPM remains poor and the median survival
ranges from 8 to 14 months [3]. Several prognostic factors have been
proposed, with histopathological subtype, age, sex, performance status,
treatment, blood cell count and stage identified as the most important
ones [4].
Computed tomography (CT) imaging is the primary diagnostic
modality for pleural diseases. The most common CT findings in MPM
are pleural effusion and nodular pleural thickening. Pleural plaques
with or without calcification are found in approximately 20% of MPM
patients [5]. Magnetic resonance imaging (MRI) and positron emission
tomography (PET) may give additional information on tumor assess-
ment or staging [6].
A new tumor, node, metastases (TNM 8th edition) classification has
been proposed by the International Association for the Study of Lung
Cancer (IASLC) and it has been integrated into the 8th edition of the
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American Joint Committee on Cancer/Union for International Cancer
Control (AJCC/UICC) staging [7]. The major changes in clinical and
pathological classifications are that the new T1 group combines the
previous T1a with T1b groups, and the previous N1 and N2 groups
merge into a new N1 group. There are no changes in the M groups
[8,9].
Mesothelioma grows typically in an irregular, rind-like extension
along the pleural surface with invasion into the lung parenchyma,
mediastinum, chest wall, and diaphragm [10]. Because of the unusual
growth pattern, there have been several different attempts for the
quantification of MPM besides the TNM classification. Tumor volume
quantified either manually or semi-automatically has been found to
associate with survival and therapeutic responses [11,12]. Additionally,
the sum of several multilevel measurements of tumor thickness has
been the standard assessment for treatment response and identified as
an independent predictive factor for patients after radical therapy
[13,14].
In this retrospective study, we investigated the CT characteristics of
MPM at the time of diagnosis in a representative study population. We
defined a novel and simple approach for CT-based tumor size evalua-
tion using the maximal tumor thickness and the tumor extension along
the chest wall. The purpose was to create an easy and reproducible
estimation that would reflect the tumor burden. Secondly, we assessed
the usefulness of the novel TNM classification for the evaluation of
patient survival and factors that contribute to the baseline clinical
stage.
2. Material and methods
2.1. Patients
This retrospective cohort study was a part of an epidemiological
research project that explores MPM in Finland between 2000 and 2012
with 1010 patients identified from the Finnish Cancer Registry (FCR), a
nationally comprehensive cancer registry (Laaksonen, in press). We
have retrospectively reviewed a subcohort of that study, namely 161
patients who had CT studies available at the time of the diagnosis (years
2007–2012) from the Hospital District of Helsinki and Uusimaa (HUS).
Survival follow-up closed on February 17, 2017, or at the time of the
patient’s death. The patient characteristics are summarized in Table 1.
The Finnish Cancer Registry is known to be of high quality and
accuracy, with a recent quality assessment showing 96% completeness
for solid tumors [15]. The data from FCR used in this study included
date of birth, gender, and histologic type. The underlying causes and
the dates of death were complemented from the National Registry of
Causes of Death at Statistics Finland. Since there is a delay in entering
the mortality rate to the death registry, a few patients’ data was au-
thenticated from the clinical records. The exact date of the diagnosis
and missing clinical data were supplemented and verified from clinical
patient records. The information on an occupational disease due to
exposure to asbestos at work was collected from the Finnish Workers’
Compensation Center. Five (3%) patients with a suspicion of occupa-
tional disease were considered having received compensation. The
study was approved by the ethics committee of the Helsinki University
Hospital (418/13/03/02/2015).
The histopathological diagnosis of MPM was obtained by thick
needle biopsies from 71 patients (44%) and surgical biopsies from 89
patients (55%). In addition, one (1%) patient was diagnosed post
mortem. The histological diagnosis was made at the Helsinki University
Hospital according to morphological and immunohistochemical criteria
evaluated by an experienced pathologist. All of the cases were reviewed
in an oncological multiprofessional team. The mesothelioma subtype
was not specified in 16 cases (10%) in the original dataset. One of the
authors (H.W.) with experience in mesothelioma diagnostics evaluated
the written pathology reports of these 16 cases and assigned the sub-
type based on the reports.
2.2. Imaging
The pretreatment CT scans taken closest to the date of the diagnosis,
either prior to or after it, were analyzed. The mean interval between the
diagnosis and the CT scan was 2.0 months (SD 3.0). The spiral CT
images were performed using different scanners and imaging protocols
as in use in various hospitals. At the beginning of the study period CT
imaging was mainly axial with slice thickness about 5mm. Due to the
natural evolution of CT technology, thinner images with a typical slice
thickness of 2,5–3mm and multiplanar reconstruction were used later
on. One hundred and eighteen patients (73%) had coronal and/or sa-
gittal images in addition to axial images, while 43 (27%) patients had
axial images only. In 17 (11%) cases only chest images were available;
in the rest 144 (89%) cases the imaged area also covered abdomen. No
brain scans were available. Intravenous contrast medium was used if
not contraindicated. A contrast-enhanced CT was available on 152
(94%) patients. CT scans were evaluated in a blinded fashion by a se-
nior radiologist specialized in occupational diseases (T.V.). A set of 30
(19%) images were re-evaluated one month later by the same radi-
ologist to determine the intra-rater agreement. The images were in-
spected and measurements performed by using the Impax CS5000 work
station (Agfa Health Care Finland) supplied with Barco NIO 2MP grey-
scale monitors.
Mesotheliomas were radiologically staged by using the proposed 8th
edition of the AJCC/UICC staging system [7]. Tumor thickness was
evaluated in axial planes perpendicular to the chest wall or medias-
tinum, and the apparently maximal value was measured. To approx-
imate the extension of the tumor in the pleural cavity, we used a pre-
viously published method for evaluating pleural abnormalities [16].
First, the pleural cavity was divided into three zones: the upper zone
(arch of the aorta to lung apex), the middle zone (from the arch of the
aorta down to the inferior pulmonary vein) and the lower zone (from
the inferior pulmonary vein to the diaphragm). The slice with the
greatest extension of the tumor was evaluated separately for each of the
three zones, and the final extension was virtually summated at the level
of carina. The final extension was graded at a 4-point scale (0=no
tumor, 1≤ 90°, 2= 90–180°, 3≥ 180° of the pleural circumference at
the carina level) [17] (Fig. 1). Tumor size (TS) was then estimated by
multiplying the measured maximal tumor thickness with the above
Table 1
Overview of patient characteristics (n= 161).
Characteristics Value












Compensated occupational disease; n (%)a
Yes 109 (68%)
No 52 (32%)
Cause of death; n (%)
MPM 153 (95%)
Other cause 2 (1%)
Aliveb 6 (4%)
a Information from the Finnish Workers’ Compensation Center.
b Alive at the end of the study period (17.2.2017); MPM, malignant
pleural mesothelioma.
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tumor extent grade.
Pleural plaques and calcifications were recorded from both pleural
sides separately (yes= 1, no=0), and then combined into one metric
(bilateral existence/absence). The maximal axial thickness of pleural
effusion was measured. The fibrosis and emphysema scores were
evaluated on a previously published scale, where 0 represents no pa-
thology and 5 extreme changes [18,19] (Table 2).
2.3. Statistical analysis
Statistical analyses were performed using SAS version 9.4 (SAS in-
stitute, Inc. Cary, NC) and figures were drawn with SPSS version 24.0
(IBM SPSS Statistics, Chicago, IL). A p-value< 0.05 was considered
significant. Intra-observer agreement was defined using weighted
kappa (wκ) for categorical variables and intra-class correlation coeffi-
cient (ICC) for continuous variables [20,21]. The Spearman rank cor-
relation coefficient was calculated to assess the pairwise relationship of
tumor size with age, pleural effusion and TNM stage. The associations
between radiological findings and histological subgroups, TS and stage
were evaluated by the Kruskal-Wallis analysis of variance.
The proportional odds model for logistic regression was used for
analyzing the independent variables’ associations with the TNM stage.
The potential predictors considered for the TNM stage were pleural
effusion, pleural plaques and calcification, age, sex, histology, com-
pensated asbestos exposure-related occupational disease, fibrosis and
emphysema. The survival analysis was carried from the date of the
diagnosis to the end of the follow-up or until death. Both all-cause and
disease-specific mortalities were recorded, and since only two (1%)
patients died of other causes than MPM, the latter was used in the
analyses. The survival curves were computed using the Kaplan-Meier
method, and the log rank test was used to determine statistical sig-
nificance between the TS, tumor extent grade and stage groups. We
stratified TS into quartiles (low 0–11, middle 12–79 and high 80–306)
for the Kaplan-Meier analysis. The Cox regression was used for the
univariate and multivariate survival analyses. The coefficient of de-
termination for the final multivariate model was calculated [22]. The
predictors identified by the univariate model (TS, laterality, pleural
effusion, stage, histology, age and pleural calcification) as well as
gender were included in the final multivariate model. Because of the
small number of patients in different stage groups, we combined stages
IA, IB with II and IIIA with IIIB in the survival models. We added a
variable that considers the signs of thoracentesis or pneumothorax to
adjust for pleural effusion in multivariate models.
3. Results
3.1. Radiological characteristics at diagnosis
There were 161 MPM patients diagnosed between 2007 and 2012 at
HUS district with CT-images available. The most common CT findings
were pleural thickening and pleural effusion, which were found on 149
(93%) and 144 (89%) cases, respectively. Most of the patients had stage
IB (20%) or IIIB (37%) disease, while 12 (7%) patients had no re-
cognizable tumor in the CT scan (Table 2). Univariate analysis between
TNM stage and clinicopathological factors gave no statistically sig-
nificant results, therefore a multivariate model was not applied. The
right sided tumors tended to be more advanced (p= 0.090). The intra-
observer agreements are summarized in Table 3. They were mostly
good to excellent, except for metastasis and emphysema scale where
they were fair to moderate.
3.2. Tumor size and itś relationship to other radiological parameters
The distribution of TS estimation was rightward skewed with the
median value of 36 (0–306). There were differences with TS according
to different histological subgroups (p= 0.003, Kruskal-Wallis analysis
of variance): The median size of the sarcomatoid type was 66 (12–306),
epithelioid 33 (0–213), and biphasic 16 (0–156). There was also an
association between tumor thickness and histological subtypes
(p= 0.003, Kruskal-Wallis analysis of variance), while other CT-find-
ings failed to show such relations. The TS increased along with an ad-
vancing tumor stage (p < 0.0001), except for the stage 2 disease where
patients are classified with T1-T2N1 disease (Fig. 2). The TS correlated
with TNM T-class (r= 0.70, p < 0.0001), N-class (0.41, p < 0.0001),
Fig. 1. The extension of the tumor in the pleural cavity. The pleural cavity is divided into
three zones: the upper zone (arch of the aorta to lung apex), the middle zone (from the
arch of the aorta down to the inferior pulmonary vein), and the lower zone (from the
inferior pulmonary vein to the diaphragm). The tumor extension is evaluated separately
for each of the three zones, and the final extension is summed and graded at the level of
carina. Modified from Kusaka Y et al. with permission [17].
Table 2
Overview of the CT findings.
CT Finding Value
Pleural effusion (mm); median (range) 50.0 (0–165)
Tumor thickness (mm); median (range) 18.0 (0–102)
Tumor size; median (range)a 36.0 (0–306)
Tumor extent; n (%)
Grade 0 12 (7%)
Grade 1 53 (33%)
Grade 2 32 (20%)
Grade 3 64 (40%)
Bilateral pleural plaques; n (%) 99 (62%)
Bilateral pleural calcification; n (%) 74 (46%)
Fibrosis, 0–5; n (%)
Scale 0 120 (74%)
Scale 1 30 (19%)
Scale 2 10 (6%)
Scale 3 1 (1%)
Emphysema, 0–5; n (%)
Scale 0 111 (69%)
Scale 1 42 (26%)
Scale 2 7 (4%)
Scale 4 1 (1%)
Radiological stage; n (%)
Stage 0 12 (7%)
Stage IA 14 (9%)
Stage IB 32 (20%)
Stage II 5 (3%)
Stage IIIA 14 (9%)
Stage IIIB 60 (37%)
Stage IV 24 (15%)
a Tumor size estimated by multiplying the measured maximal tumor thickness with
the 4-point tumor extent grade of the pleural circumference at the carina level.
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and stage (r= 0.69, p < 0.0001), while no significant correlation was
found between TS and age or pleural effusion. TS differed between the
M0 status (median 29) and M1 status (median 84) (p=0.003, Mann-
Whitney U test).
3.3. Prognostic implications of radiological assessment and tumor size
measurement
The median length of follow-up was 9.7 (range 0–104) months and a
total of 214.0 person years were included in the follow-up. The median
survival of this cohort was 9.1 (range 0–104) months. Six (4%) patients
were still alive at the end of the study period. The Cox regression
analyses for survival are summarized in Table 4. The univariate analysis
showed that TS, age, laterality, pleural effusion, pleural calcification,
histology and radiological stage were associated with mortality. Lung
parenchymal fibrosis (p= 0.690) or emphysema (p= 0.596) had no
association with survival. In multivariate analyses TS, pleural effusion
along with non-epithelioid histological subtype were individual pre-
dictors of poor survival. When both tumor thickness and extent grade
were added to the final model instead of TS, only tumor extent proved
to be an independent predictor of mortality (p=0.001). The TNM
stage was suggestively associated with mortality in univariate analysis
(p= 0.075) but not after multivariate adjustment (p=0.225). The
coefficient of determination for the final multivariate model was 0.361,
while the individual values for histology, TS and TNM stage were,
0.190, 0.107 and 0.051, respectively. It is related to the proportion of
variance in the model explained by the independent variables, thus
implicating that TS was a better predictor for survival than the TNM
stage.
In Kaplan-Meier analysis the median survival was lowest in TNM
stage IV (median 6.3, range 0.4–50.6 months) and highest in stage 0
(median 24.1, range 2.1–87.5 months), while there was no difference
between stage groups I–III (p= 0.776) (Fig. 3A). When the tumor size
variant was classified into three groups, survival of the lowest quartile
was significantly higher than in the remaining groups (p=0.016). The
median survival in the lowest quartile was 14.0 (range 0.5–103.6)
months compared to 11.1 (range 0–79.7) months in the middle and 5.4
(range 0–68.7) months in the highest quartile (Fig. 3B). Furthermore,
the extent grade alone proved to be a significant prognostic factor
(p < 0.001) (Fig. 3C).
4. Discussion
This is one of the first studies to use the 8th revised TNM classifi-
cation for CT-based MPM evaluation. We found that in our well-defined
cohort of MPM patients, a simple tumor size estimation was a stronger
Table 3
Intra-rater agreement for CT-findings.





Bilateral plaques 0.86 0.66–1.00
Bilateral calcification 1.00 1.00–1.00
Fibrosis scale 0.75 0.55–0.95
Emphysema scale 0.41 0.08–0.73
Tumor extent 0.84 0.70–0.98
Tumor thickness 0.92 0.84–0.96
Tumor size 0.93 0.85–0.96
Pleural effusion 0.97 0.94–0.99
Wκ, weighted kappa; ICC, Intraclass correlation coefficient; Cl, confidence interval.
Fig. 2. The boxplot demonstrates tumor size distribution between different radiological
stages.
Table 4
Factors associated with survival.
Unadjusted Adjusteda
Variable HR (95% Cl) p-value HR (95% Cl) p-value
Age (continuous) 1.02 (0.99–1.04) 0.061 1.02 (1.00–1.04) 0.144
Sex, male 1.05 (0.66–1.67) 0.828 1.13 (0.68–1.88) 0.640
Side, right 1.36 (0.98–1.88) 0.067 0.99 (0.70–1.42) 0.966
Effusion (continuous) 1.01 (1.00–1.01) 0.038 1.01 (1.00–1.01) <0.001
TS (continuous) 1.01 (1.00–1.01) < 0.001 1.01 (1.01–1.02) <0.001
Pleural calcification, yes 1.39 (1.01–1.91) 0.046 1.22 (0.84–1.78) 0.298
Histology
Epithelioid 1.00 1.00
Sarcomatoid 4.46 (2.83–7.04) < 0.001 4.71 (2.88–7.69) <0.001
Biphasic 1.61 (1.02–2.54) 0.043 2.07 (1.27–3.38) 0.003
Radiological stage
Stage 0 1.00 1.00
Stage I+ II 2.10 (1.06–4.16) 0.034 1.60 (0.78–3.28) 0.197
Stage III 2.22 (1.14–4.33) 0.019 1.06 (0.50–2.24) 0.879
Stage IV 2.66 (1.26–5.60) 0.010 1.20 (0.49–2.94) 0.690
Occupational disease, yes 0.95 (0.67–1.33) 0.744
Pleural plaques, yes 1.17 (0.84–1.63) 0.340
HR, hazard ratio; Cl, confidence interval; TS, tumor size.
a Cox regression model adjusted with age, sex, side, pleural effusion, TS, bilateral pleural calcification, histology, stage and signs of thoracentesis.
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predictor for mortality than the traditional TNM stage. Also, we ob-
served that non-epithelioid histology and the amount of pleural effusion
are markers for worse prognosis in mesothelioma patients.
Clinical staging of MPM patients is critical for appropriate treatment
decisions and for evaluating the effectiveness of given treatment [23].
Although CT remains the primary modality for MPM evaluation due to
its accessibility, there are some well-known limitations regarding tumor
assessment and staging [24]. The current TNM T classification is based
only on invasion to adjacent structures and it does not take into account
the actual size of the tumor. CT tends to underestimate the tumor extent
and most patients are upstaged during surgery [9]. Furthermore, CT
based nodal evaluation has been reported to be poor when comparing
to nodal sampling, thus some centers recommend pre- or perioperative
lymph node sampling to rule out N2 disease [25]. Limitations in CT
based staging may explain that in this present study the TNM staging
failed to be an independent factor for survival. Most MPM patients are
diagnosed at locally advanced disease [26], which was the case also in
this study. In turn, MPM can exist even in a CT scan that appears
normal. In our series, there were 12 (7%) patients with no distinct
tumor findings in CT, but who were diagnosed from a surgical pleural
biopsy. Similar reports have been previously published [27].
Some studies have suggested that assessing tumor thickness or vo-
lume could replace or supplement the TNM T category [7,28]. Tumor
volume is a more comprehensive and better studied measure than its
thickness, but assessing the exact tumor volume from CT images can be
complex, time-consuming and prone to errors. No single volumetric
application has still not been introduced for universal clinical use. Ei-
ther single unidimensional maximal tumor thickness or the sum of three
separated pleural thicknesses measured at the upper, mid, and lower
regions were correlated with survival and nodal metastases [9]. Manual
measurements have been criticized for their inter-observer variability
and semi-automated thickness measurements has been suggested
[23,29]. In this study, we used tumor thickness as part of tumor size
evaluation and have demonstrated a strong relationship between TS
and mortality, TNM classification and sarcomatoid histology. In addi-
tion, we found that tumor extent grade was a more powerful predictor
for survival than tumor thickness.
In our study, the thickness of pleural effusion was another in-
dependent factor for poor prognosis. Pleural effusion can be the first
presentation of MPM, but there are only few studies with contradicting
results regarding its prognostic value. Tanrikulu et al. showed that the
presence of pleural effusion was associated with a poor prognosis [30].
In a recent study, malignant pleural effusion in mesothelioma demon-
strated active biological properties [31]. Thus, the presence of effusion
might reflect the activity of the disease. However, this measurement
can be biased by previous thoracentesis, even though we tried to adjust
for that. Tumor laterality has previously been reported as a prognostic
factor, but the reason for that remains unknown [32]. Here, we also
found that right-sided tumors had a worse prognosis and they were
found to be more advanced at the time of diagnosis.
Apart from mesothelioma, asbestos exposure is known to be asso-
ciated with asbestosis, pleural plaques and calcification. In previous
publications, the association between benign pleural disease and me-
sothelioma has been controversial [33]. Pleural plaques are reported to
be the most common marker of a previous asbestos exposure and a large
screening study for patients with a history of occupational exposure to
asbestos showed that the presence of pleural plaques was an in-
dependent risk indicator for MPM [34]. The prevalence of pleural
plaques and calcification in this study is higher than previously pub-
lished in MPM patients, but similar to other Finnish asbestos-exposure
studies [35]. Calcification of the pleura was also associated with a poor
survival in univariate analyses, which hasn’t been reported before in
MPM patients. However, pleural plaques were associated with all-cause
mortality and both pleural plaques and calcification were predictors for
thoracic cancer mortality in a follow-up study of asbestos-exposure
patients without MPM [36]. Even though both asbestos-induced
Fig. 3. Kaplan-Meier curve for survival according to A) radiological stage, B) tumor size,
C) tumor extent grade. mS, median survival.
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pulmonary fibrosis and MPM are linked to asbestos exposure in a dose-
dependent manner, there is a lack of publications about their re-
lationship with each other [37]. In the present study, the lung par-
enchymal fibrosis and emphysema were mainly absent or minor. In this
respect, the power of our analysis was limited to show their association
with the outcome.
4.1. Limitations of the study
The main limitation of our study is its retrospective design. The
variability of CT imaging can affect the imaging measurements, but that
is unavoidable in a retrospective study like this. Our study population is
relatively large considering the rarity of this disease. Still, stratifying
patients in many TNM groups leads to poor power. A clear advantage of
the new TNM system is that no attention is paid to the fact whether the
tumor involves the visceral or parietal pleura, because they can seldom
be separated in CT images.
Only a single experienced radiologist was available for this project,
thus the inter-reader agreement was not measured. The intra-rater re-
producibility for CT findings was good to excellent, except for the
emphysema scale and metastasis. The reason for the first was especially
the difficulty to separate between minimal emphysema and a normal
finding. This may become easier as more modern CT equipment is
implemented to hospitals. It is also almost impossible to know whether
an incidental mass distant from the tumor is a sign of metastasis or not.
Such sign may be divergently classified. The divergent technology of
multicenter CT imaging may also have introduced some inconsistency
in image reading.
4.2. Conclusions
In conclusion, we launched a novel MPM size evaluation that has a
strong relationship with mortality, sarcomatoid histology and the TNM
stage groups. Our results suggest that TS could be used for refining the
prognostic evaluation of MPM patients with the new TNM classifica-
tion. Further studies are needed to evaluate whether TS could be a
useful tool in assessing treatment responses. In addition, both non-
epithelioid histology and the amount of pleural effusion were in-
dependent markers for a worse prognosis.
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